InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company’s Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce…
Software Upgrade Improves Optical Biometry In Eyes With Severe Cataracts
New software enhanced optical biometry and axial length measurement in eyes slated for cataract surgery, a study found.
InSite Vision Completes Patient Enrollment In ISV-303 Phase 1/2 Clinical Study For Post-Surgical Ocular Pain And Swelling
InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company’s Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce…
Online Health Info Popular but Often Unchecked
The number of people looking for health information online is set to soar as workers return from holiday breaks, but few will check where the information comes from, according to an international survey released Tuesday. Reuters Health Information
Iluvien Update: FDA Marketing Approval Delayed
Last July, I wrote a comprehensive report about Iluvien and the status and promise of other sustained release drug delivery systems (Iluvien and the Future of Ophthalmic Drug Delivery Systems). At that time, Alimera Sciences, the company developing Ilu…
Guidance on the referral of glaucoma suspects by community optometrists
This guidance relates to asymptomatic patients, those with symptoms should be treated according to current protocols. The guidance relates only to suspected glaucoma.
Published 20 December 2010, updates previous guidance of 17 December 2009.